Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer

Published:2024-05 Issue:5 Volume:27 Page:109801
ISSN:2589-0042
Container-title:iScience
language:en
Short-container-title:iScience

Author:

Knisely Anne,Hinchcliff Emily M.,Gardiner Elisabeth,Rangwala Reshma,Lito Kathryn,Fellman Bryan,Yuan Ying,Sood Anil K.,Westin Shannon N.,Lu Karen H.,Jazaeri Amir A.

Funder

AstraZeneca UK Limited

University of Texas MD Anderson Cancer Center

AstraZeneca

Aravive, Inc.

NCI

National Institutes of Health

Publisher

Elsevier BV

Reference31 articles.

1. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer;Zhang;N. Engl. J. Med.,2003

2. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study;Matulonis;Ann. Oncol.,2019

3. Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA);Hamanishi;J. Clin. Oncol.,2021

4. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial;Disis;JAMA Oncol.,2019

5. Immunotherapy in ovarian cancer;Odunsi;Ann. Oncol.,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP